Artiva Biotherapeutics awarded Chief Tech Operations Officer Horan Christopher 40,000 shares at $0 per share and 120,000 derivative securities on September 9, 2026. The awards left him with 323,084 shares and 120,000 derivative securities, representing about 12.4% and 100.0% of those respective holdings.

Key Highlights

  • Horan Christopher’s resulting common-share holding was 323,084 shares.
  • The executive received 120,000 derivative securities in a separate award.
  • The 40,000-share transaction represented about 12.4% of his resulting share holding.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Tech Operations Officer Horan Christopher 40,000 shares at $0 per share on September 9, 2026.

Award Includes Shares and Derivative Securities

Horan Christopher also received 120,000 derivative securities on September 9, 2026. That award was recorded under the same transaction code A. His resulting derivative-securities holding was 120,000. The stock award left him with 323,084 shares. Artiva Biotherapeutics identifies Christopher as its Chief Tech Operations Officer. The share award carried a price of $0 per share.

Awards Measured Against Resulting Holdings

The 40,000 shares represented about 12.4% of Christopher’s resulting holding of 323,084 shares. The 120,000 derivative securities represented about 100.0% of his resulting derivative-securities holding of 120,000. The percentages apply to different holdings. One measures the common-share award against shares held after the transaction, while the other measures the derivative-securities award against derivative securities held afterward. Transaction code A denotes an award, grant, or other Acquisition from the company.